Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.

@article{Metz2012EvaluationOA,
  title={Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.},
  author={Thomas F. Metz and Thomas P. Mechtler and Michael Merk and Aenne Gottschalk and Richard Luka{\vc}in and Kurt R. Herkner and David C. Kasper},
  journal={Clinica chimica acta; international journal of clinical chemistry},
  year={2012},
  volume={413 15-16},
  pages={
          1259-64
        }
}
Newborn screening for tyrosinemia type I (Tyr-I) is mandatory to identify infants at risk before life-threatening symptoms occur. The analysis of tyrosine alone is limited, and might lead to false-negative results. Consequently, the analysis of succinylacetone (SUAC) is needed. Current protocols are time-consuming, and above all, include hazardous reagents such hydrazine. We evaluated a novel, commercial kit to analyze amino acids, acylcarnitines and SUAC with a significantly less harmful… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.Mol Genet Metab 2006;88:16–21

MageraMJ, GunawardenaND, SH Hahn
  • 2006
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project

McHughDM, CA Cameron, JE Abdenur
  • Genet Med
  • 2011
VIEW 1 EXCERPT